Qvents

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

EC Issues Annexure 22 – Draft Guid

The European Commission (EC) has published a draft guidance – Annexure 22 – Artificial Intelligence

Glenmark Pithampur Facility Issued USFDA

USFDA has issued a Warning letter to Glenmark Pharma’s Pithampur manufacturing facility (FEI 3008565058). The

New NSCLC Drug Approved by USFDA –

China’s rise in cutting-edge pharmaceutical innovation received a major fillip with the USFDA approval of

USFDA Publishes 200+ CRLs: Gives Insight

USFDA has published over 200+ redacted Complete Response Letters (CRLs) issued to drug applicants. The

FDA Extends Nitrosamine Timelines

USFDA has allowed drug manufacturers additional time for submission of mitigation actions and required changes

CDSCO’s NSQ Alerts – May 2025: Centr

Indian drug regulator CDSCO has published the Not of Standard Quality (NSQ) alert lists for

USFDA Issues Final Guidance for PFC For

USFDA has issued the final guidance for Pre-Submission Facility Correspondence (PFC) for prioritised generic drug

Yiling Pharma Warning Letter: Equipment

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter in June 2025

Data Integrity Concerns: USFDA Issues No

The USFDA issued a notification on 22 May, 2025 on Data Integrity concerns on reliability

CDSCO Updates Export NOC Procedure for N

Indian regulatory agency, CDSCO has updated the requirements for application and issuance of Export NOC